Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Stock Short Interest Climbs 95.6%

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 164,782 shares, a growth of 95.6% from the September 15th total of 84,256 shares. Based on an average trading volume of 2,143,151 shares, the short-interest ratio is presently 0.1 days. Currently, 2.5% of the company’s shares are short sold.

Creative Medical Technology Stock Performance

NASDAQ CELZ traded down $0.03 during trading on Wednesday, hitting $0.79. The stock had a trading volume of 71,537 shares, compared to its average volume of 3,260,549. The stock has a market capitalization of $5.17 million, a price-to-earnings ratio of -0.38 and a beta of 2.06. Creative Medical Technology has a one year low of $0.62 and a one year high of $6.25. The stock has a 50 day simple moving average of $1.04 and a 200 day simple moving average of $1.54.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, sell-side analysts predict that Creative Medical Technology will post -1.18 EPS for the current year.

Wall Street Analyst Weigh In

CELZ has been the topic of several recent analyst reports. Wall Street Zen raised shares of Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Weiss Ratings lowered shares of Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. Finally, Roth Capital restated a “buy” rating on shares of Creative Medical Technology in a report on Thursday, August 20th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc is a clinical-stage biotechnology company focused on developing regenerative medicine and cellular therapies. The company’s research uses adult stem cells and other cell-based approaches intended to address conditions with limited treatment options, including immune, neurological, metabolic and urological disorders.

Its development programs have included CaverStem, an autologous bone marrow-derived cell therapy platform being investigated for erectile dysfunction, as well as ImmCelz and NeuroCelz programs designed to explore cell-based treatments for immune-related and neurological conditions.